
Bioxodes closes €12 million in Series A funding round
November 21, 2023
Gosselies, Belgium
Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage. Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023